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made on the basis of data that subsequently become available. In
the discussion, we describe a 2% to 12% 30-day or hospital
mortality among patients undergoing rescue angioplasty, but it is
clear from the reference section that this includes data from studies
published after initiation of the MERLIN trial.
It is extraordinary for the authors to suggest that we made the
comment that 3,000 patients would be needed to show mortality
benefit and that, knowing this, we went on to perform a trial on
300 patients. First, this comment does not actually appear in our
study, having been removed (not at our request) during the review
and editing process. Second, the figure of 3,000 is an estimation of
the number required in each of the two arms in order to
demonstrate significant reduction in coronary mortality at the levels
we observed (11% conservative vs. 8.5% rescue). Their comments
imply that the authors have not understood our power calculation
and also that they have either reviewed our original study and been
subsequently unaware of changes made by the editorial team, or
been given the wrong draft to comment on in the editorial process.
We have not stated that the primary end point in the MERLIN
trial is negative, but instead that we failed to demonstrate mortality
benefit. Presentation of the results in open forum suggests that
those in favor of rescue angioplasty have seen a slight benefit in
mortality, as well as the perceived advantages of the combined end
point, and interpret this as a reason to continue a rescue program.
Conversely, skeptics interpret our results as confirming their belief
that rescue angioplasty is performed too late to be beneficial.
We agree that the majority (56%) of our patients had nonant-
erior infarction, but this is not the same as inferior infarction and
does not imply anything about infarct size. The investigators state
that randomized trials and American Heart Association/American
College of Cardiology guidelines suggest that clinical benefit from
rescue angioplasty is confined to anterior myocardial infarction
(MI). However, this is based almost entirely on data from the
RESCUE trial (3), with its limitations as described. No random-
ized trial has demonstrated lack of benefit from rescue angioplasty
in patients with nonanterior MI.
Despite the above comments, we suspect there is no major
conflict. A successful rescue angioplasty frequently benefits the
patient: the vessel opens, flow is restored, the ST segments come
down, and there are no complications. However, it is an omission
to make no comment on the potential for harm. The challenge is
to identify those patients with most to gain and the lowest risk of
harm.
We have not abandoned rescue angioplasty, and certainly not
abandoned the open-artery hypothesis. We believe that primary
angioplasty is the best treatment for ST-segment elevation myo-
cardial infarction. However, while patients continue to receive
fibrinolytics for ST-segment elevation myocardial infarction, the
question of rescue remains. Our approach is a selective one, in line
with the editorial view. Our current focus is on how to deliver
primary angioplasty to a large population in the northeast of
England with equitable access to care for all patients. If this can be
achieved, the unanswered dilemmas of rescue angioplasty will
become relatively less important.
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REPLY
We thank Drs. Sutton and Belder for their interest in our paper (1)
and again wish to compliment Sutton et al. (2) on undertaking the
largest rescue angioplasty trial conducted to date. It appears that
we were using an earlier version of the study when commenting on
the required sample size of 3,000 patients, and for this we
apologize. But all parties agree that one could not expect a
significant reduction in mortality given the small sample size and
control group mortality of only 11%.
Although we can debate whether nonanterior myocardial in-
farction (MI) is the same as inferior MI, it is clear that patients
who present with inferior ST-segment elevation have a smaller
infarct size (3) and better prognosis than patients with anterior MI
(4). Moreover, given the low baseline risk of inferior MI patients,
it has been difficult to prove a mortality advantage with reperfusion
therapy compared to placebo (4).
So what have we learned from the MERLIN trial? It is clear
that rescue angioplasty has room for improvement. Consistently,
rates of Thrombolysis In Myocardial Infarction (TIMI) flow grade
3 after rescue percutaneous coronary intervention (PCI) are lower
than those reported after primary PCI. We had hoped that
extraction of thrombosis or use of distal protection devices would
improve perfusion and clinical outcomes. Yet large, randomized
trials using distal protection (EMERALD trial) or thrombectomy
(AIMI trial) showed no improvement in TIMI flow grades,
myocardial blush scores, infarct size, or major adverse cardiac
events compared to PCI alone (5). The lack of benefit may have
been due to embolization with saline agitation, advancing the
device past the thrombotic lesion or diverting emboli into proximal
side branches. Therefore, it is possible that use of lower-profile
thrombectomy catheters, filters, or proximal protection devices
may be of benefit.
We agree with the MERLIN investigators that the focus should
not be on rescue PCI, but on how to deliver primary angioplasty to
a larger population. Performance of primary PCI (by an experi-
enced PCI operator) in a diagnostic-only catheterization labora-
tory would increase availability enormously. We should work
toward a goal of performing prehospital electrocardiography and
transferring patients with ST-segment elevation myocardial infarc-
tion from home, directly to a primary PCI center.
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Definition of Failed Lysis May Have
Influenced Outcome in the MERLIN Trial
We note with great interest the findings of the recent MERLIN
trial (1). We congratulate the investigators on their attempts to
evaluate prospectively the efficacy of rescue angioplasty in this
randomized controlled trial. We would, however, like to point out
a few potential confounding factors that may have had an impor-
tant effect on the findings.
We note that the definition used for failed lysis was “a second
ECG [electrocardiogram] at 60 min after onset of lytic therapy,
showing failure of the ST-segment elevation in the worst lead to
have resolved by 50%, as compared with the pre-treatment ECG,
as well as the presence of an accelerated idioventricular rhythm at
the time of the 60-min ECG.” We believe this definition of failed
lysis may have clearly influenced the outcome of the trial. As
acknowledged in the accompanying editorial (2), the time of 60
min may have led to more patients being taken for coronary
angiography than if 90 min were used. It is possible that a number
of patients who were in the failed lysis category may in fact have
had successful lysis if 90 min had been used. Clearly, this would
have influenced the outcome measures used in the MERLIN trial,
as those patients who were randomized to percutaneous coronary
intervention (PCI) for failed lysis at 60 min may not have been
taken to the catheterization laboratory if a 90-min ECG had
shown resolution. At our institution we evaluate whether failed
lysis has occurred at 90 min post-lytic therapy, allowing more time
for lysis therapy to take effect; this may reduce not only the number
of patients taken to the catheterization laboratory but also the
number of patients exposed to a procedure with a definite risk.
The other important issue was the absence of any mention of
ongoing chest pain. When assessing the possibility of failed lysis
we, at our institution, always assess whether the patient has
ongoing chest pain. This forms an important part of the evaluation
of whether a patient is taken for angiography in the first place.
Continual chest pain is regarded as a very good indicator of failed
lysis and recommended as an important noninvasive marker for
defining failed lysis (3). Some of the patients in the MERLIN trial
who were entirely pain free may have undergone angiography;
these patients might have been exposed to a procedure with a risk
involved and hence affected the outcome parameters assessed.
We acknowledge the lack of large randomized trials in this field,
and once again congratulate the investigators on their attempt to
answer this important question. We hope further studies in this
area will add to the emerging evidence regarding rescue angio-
plasty.
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REPLY
We thank Dr. Osman and colleagues for their interest in the
MERLIN trial report (1). We would like to address their com-
ments on potential confounding factors.
First, they appear to have misread the protocol definition for
failed fibrinolysis, which was “a second ECG [electrocardiogram]
60 min after the onset of fibrinolytic therapy showing failure of the
ST-segment elevation in the worst lead to have resolved by 50% by
comparison to the pre-treatment ECG as well as the absence of an
accelerated idioventricular rhythm at the time of the 60-min
ECG.”
Second, we debated the most appropriate method of diagnosing
failed fibrinolysis, specifically the timing of the second ECG. In a
previous study we assessed the ability of a 2-h ECG, performed
immediately before coronary angiography, to predict flow in the
infarct-related vessel (2). In the MERLIN trial we elected to
diagnose failed fibrinolysis at 60 min for the following reasons: a)
time is muscle, particularly when the initial reperfusion strategy is
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